Literature DB >> 11330408

Effect of resistant starch on potential biomarkers for colonic cancer risk in patients with colonic adenomas: a controlled trial.

M J Grubben1, C C van den Braak, M Essenberg, M Olthof, A Tangerman, M B Katan, F M Nagengast.   

Abstract

Resistant starch decreases the concentration of secondary bile acids in the feces and the proliferation rate of colonic mucosal cells in healthy volunteers. This may reduce the risk of colon cancer. We investigated 23 patients with recently removed colonic adenoma(s) in a controlled parallel trial. They consumed 45 g of maltodextrin per day as placebo for four weeks and were randomly assigned to either 45 g of native amylomaize starch, containing 28 g of resistant starch type II or 45 g of maltodextrin for another four weeks. No effect on colorectal cell proliferation, fecal wet and dry weights, pH, and short-chain fatty acid excretion was seen. The bile acid concentration in fecal water decreased by 15% (P = 0.048) and the percentage secondary bile acids decreased by 14% (P = 0.002) on resistant starch relative to placebo. Whether this has a substantial role in colon cancer prevention in these patients remains to be established.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11330408     DOI: 10.1023/a:1010787931002

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  53 in total

1.  Changes in fecal composition and colonic function due to cereal fiber.

Authors:  J H Cummings; M J Hill; D J Jenkins; J R Pearson; H S Wiggins
Journal:  Am J Clin Nutr       Date:  1976-12       Impact factor: 7.045

2.  Super-efficient starch absorption. A risk factor for colonic neoplasia?

Authors:  J R Thornton; A Dryden; J Kelleher; M S Losowsky
Journal:  Dig Dis Sci       Date:  1987-10       Impact factor: 3.199

3.  Effect of high fat consumption on cell proliferation activity of colorectal mucosa and on soluble faecal bile acids.

Authors:  J Stadler; H S Stern; K S Yeung; V McGuire; R Furrer; N Marcon; W R Bruce
Journal:  Gut       Date:  1988-10       Impact factor: 23.059

4.  Calcium supplementation decreases rectal epithelial cell proliferation in subjects with sporadic adenoma.

Authors:  M J Wargovich; G Isbell; M Shabot; R Winn; F Lanza; L Hochman; E Larson; P Lynch; L Roubein; B Levin
Journal:  Gastroenterology       Date:  1992-07       Impact factor: 22.682

Review 5.  Surrogate end-point biomarkers as measures of colon cancer risk and their use in cancer chemoprevention trials.

Authors:  J G Einspahr; D S Alberts; S M Gapstur; R M Bostick; S S Emerson; E W Gerner
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  1997-01       Impact factor: 4.254

6.  Effects of calcium and pH on the mucosal damage produced by deoxycholic acid in the rat colon.

Authors:  J J Rafter; V W Eng; R Furrer; A Medline; W R Bruce
Journal:  Gut       Date:  1986-11       Impact factor: 23.059

7.  Classification and measurement of nutritionally important starch fractions.

Authors:  H N Englyst; S M Kingman; J H Cummings
Journal:  Eur J Clin Nutr       Date:  1992-10       Impact factor: 4.016

Review 8.  Nutrition and colorectal cancer.

Authors:  J D Potter
Journal:  Cancer Causes Control       Date:  1996-01       Impact factor: 2.506

9.  Morphological disruption of colonic mucosa by free or cholestyramine-bound bile acids.

Authors:  G V Vahouny; S Satchithanandam; F Lightfoot; L Grau; S Haas-Smith; D Kritchevsky; M M Cassidy
Journal:  Dig Dis Sci       Date:  1984-05       Impact factor: 3.199

Review 10.  Vegetables, fruit, and cancer prevention: a review.

Authors:  K A Steinmetz; J D Potter
Journal:  J Am Diet Assoc       Date:  1996-10
View more
  6 in total

1.  A randomized placebo-controlled prevention trial of aspirin and/or resistant starch in young people with familial adenomatous polyposis.

Authors:  John Burn; D Timothy Bishop; Pamela D Chapman; Faye Elliott; Lucio Bertario; Malcolm G Dunlop; Diana Eccles; Anthony Ellis; D Gareth Evans; Riccardo Fodde; Eamonn R Maher; Gabriela Möslein; Hans F A Vasen; Julie Coaker; Robin K S Phillips; Steffen Bülow; John C Mathers
Journal:  Cancer Prev Res (Phila)       Date:  2011-05

2.  Cancer Prevention with Resistant Starch in Lynch Syndrome Patients in the CAPP2-Randomized Placebo Controlled Trial: Planned 10-Year Follow-up.

Authors:  John C Mathers; Faye Elliott; Finlay Macrae; Jukka-Pekka Mecklin; Gabriela Möslein; Fiona E McRonald; Lucio Bertario; D Gareth Evans; Anne-Marie Gerdes; Judy W C Ho; Annika Lindblom; Patrick J Morrison; Jem Rashbass; Raj S Ramesar; Toni T Seppälä; Huw J W Thomas; Harsh J Sheth; Kirsi Pylvänäinen; Lynn Reed; Gillian M Borthwick; D Timothy Bishop; John Burn
Journal:  Cancer Prev Res (Phila)       Date:  2022-09-01

3.  An investigation of cross-sectional associations of a priori-selected dietary components with circulating bile acids.

Authors:  Doratha A Byrd; Rashmi Sinha; Stephanie J Weinstein; Demetrius Albanes; Neal D Freedman; Joshua Sampson; Erikka Loftfield
Journal:  Am J Clin Nutr       Date:  2021-11-08       Impact factor: 8.472

4.  Chemoprevention in Lynch syndrome.

Authors:  John Burn; John C Mathers; D Tim Bishop
Journal:  Fam Cancer       Date:  2013-12       Impact factor: 2.375

5.  Resistant starch supplementation increases crypt cell proliferative state in the rectal mucosa of older healthy participants.

Authors:  Fiona C Malcomson; Naomi D Willis; Iain McCallum; Long Xie; Arthur C Ouwehand; Julian D Stowell; Seamus Kelly; D Michael Bradburn; Nigel J Belshaw; Ian T Johnson; John C Mathers
Journal:  Br J Nutr       Date:  2020-04-13       Impact factor: 3.718

6.  Serum Total Bile Acids in Relation to Gastrointestinal Cancer Risk: A Retrospective Study.

Authors:  Songbo Li; Xiaodong Qu; Luyao Zhang; Na Wang; Min Chen; Xingyu Zhao; Jie Wang; Huanhuan Lv; Ying Qi; Lifeng Zhang; Junye Liu; Yongquan Shi
Journal:  Front Oncol       Date:  2022-06-08       Impact factor: 5.738

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.